Cargando…
Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney Fibrosis
N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) is an endogenous antifibrotic peptide. We found that suppression of AcSDKP and induction of dipeptidyl peptidase-4 (DPP-4), which is associated with insufficient levels of antifibrotic microRNA (miR)s in kidneys, were imperative to understand the mechan...
Autores principales: | Srivastava, Swayam Prakash, Shi, Sen, Kanasaki, Megumi, Nagai, Takako, Kitada, Munehiro, He, Jianhua, Nakamura, Yuka, Ishigaki, Yasuhito, Kanasaki, Keizo, Koya, Daisuke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947922/ https://www.ncbi.nlm.nih.gov/pubmed/27425816 http://dx.doi.org/10.1038/srep29884 |
Ejemplares similares
-
N-acetyl-seryl-aspartyl-lysyl-proline Inhibits Diabetes-Associated Kidney Fibrosis and Endothelial-Mesenchymal Transition
por: Nagai, Takako, et al.
Publicado: (2014) -
Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors
por: Kanasaki, Megumi, et al.
Publicado: (2011) -
N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes
por: Kanasaki, Keizo, et al.
Publicado: (2014) -
Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen
por: Nitta, Kyoko, et al.
Publicado: (2016) -
βklotho is essential for the anti‐endothelial mesenchymal transition effects of N‐acetyl‐seryl‐aspartyl‐lysyl‐proline
por: Gao, Rongfen, et al.
Publicado: (2019)